ORIGINAL ARTICLE
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
E.L. Kwak and Others
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally bioavailable ALK kinase inhibitor, produced a 57% response rate in this subgroup, with mild grade 1 or 2 toxic effects.
Y.L. Choi and Others
J.E. Butrynski and Others
